Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

Medicare’s high cost end stage renal disease patients

Merrill Goozner
Conditions
June 11, 2011
Share
Tweet
Share

Anyone who thinks America has the best health care system in the world ought to take a look at its miserable record on caring for end stage renal disease patients on dialysis.

About one of every five people who go on dialysis dies in the first year here, compared to less than one in seven in Europe and one in sixteen in Japan. Even after adjusting for age, gender, race and 25 co-morbid conditions (the primary causes of kidney failure are poorly treated diabetes and hypertension), the U.S. mortality rate is one-third higher than Europe and nearly four times the Japanese rate, according to a recent analysis. The average life expectancy of Americans on dialysis is about three years.

Taxpayers pay exorbitant sums for these poor outcomes. The Centers for Medicare and Medicaid Services, which cover treatment for end-stage renal disease, even for the non-elderly, spent $24 billion on dialysis in 2007. Just one percent of Medicare beneficiaries who are on dialysis generated a whopping 5.6 percent of the agency’s bills. Moreover, the obesity epidemic guarantees that those numbers will only shoot up in the years ahead since more than 100,000 people are now entering dialysis ever year – more than the number that die from the one of the conditions that leads to kidney failure.

You would think that the nephrology community would be up in arms over these alarming statistics, or at least looking for a less expensive and hopefully more effective way of caring for these predominantly poor patients. Yet two new studies in the Archives of Internal Medicine reveal just the opposite. A small and declining number of patients receive peritoneal dialysis, an at-home alternative that generates comparable outcomes with greater patient satisfaction at 19 percent lower cost – $53,446 per year for patients on peritoneal dialysis versus $73,008 on in-clinic hemodialysis in 2007, according to one study.

And the other study showed nephrologists do a poor job of informing patients about this three-decade-old alternative. Peritoneal dialysis (PD) has declined from 14.4 percent of the dialysis population in 1995 to 7.1 percent in 2007. In an accompanying editorial, Dr. Kirsten Johansen, a nephrologist at the University of California at San Francisco, wrote:

The data available so far have led experts to conclude that low PD utilization is, at least in part, the fault of nephrologists, who are not discussing PD options with patients, possibly owing to concern about higher mortality (which the latest study shows is incorrect), inadequate training of nephrologists, nephrologists’ bias against PD, pressures to fill HD (hemodialysis) chairs, late referral to nephrologists, and other reasons.

I was intrigued by the “pressures to fill HD chairs” statement in the editorial, so I sent Dr. Johansen an email late last night. Were there any financial incentives that encouraged nephrologists associated with the for-profit dialysis clinics that discouraged use of this less costly alternative?

“Typically the dialysis clinic owners will hire a nephrologist to be medical director,” she wrote back. “This reimbursement isn’t tied to bringing in patients but the nephrologist then has an interest in the success of the clinic, and since they have to see their patients in that unit once a week to receive maximum Medicare reimbursement, it’s better to have several patients there on each shift to increase efficiency. I don’t think there is any solid data to say that this has an impact on how well nephrologists inform patients, but many have speculated about this.”

Last year, CMS added a new benefit for end-stage renal disease patients. The agency will reimburse physicians for up to six counseling sessions just before their patients are about to go on dialysis. The agency wants more people to consider the PD alternative, which involves removal and re-infusion of an abdominal cavity fluid about four times a day and can be self-administered at home. That doesn’t sound like fun, but patients consistently rank it as a  better experience than having to go to a distant clinic three times a week for four- to six-hour sessions where they are hooked up to a machine.

If half the new dialysis patients in the U.S. chose PD over HD, Medicare could save more than $5 billion a year. The additional counseling needed to get to those rates might even jump-start the long overdue conversation about why so many people do so poorly once they’re on dialysis; why so many have failing kidneys in the first place; and what preventive measures can be taken to deal with this burgeoning public health fiasco.

Merrill Goozner is a freelance writer, independent researcher and consultant who blogs at Gooznews on Health.

Submit a guest post and be heard on social media’s leading physician voice.

Prev

Securing mobile devices in healthcare

June 11, 2011 Kevin 2
…
Next

MKSAP: 50-year-old woman with advanced multiple myeloma

June 11, 2011 Kevin 3
…

ADVERTISEMENT

Tagged as: Medicare, Patients, Specialist

Post navigation

< Previous Post
Securing mobile devices in healthcare
Next Post >
MKSAP: 50-year-old woman with advanced multiple myeloma

ADVERTISEMENT

More by Merrill Goozner

  • a desk with keyboard and ipad with the kevinmd logo

    Curbing Medicare costs: Are seniors or the government responsible?

    Merrill Goozner
  • a desk with keyboard and ipad with the kevinmd logo

    Will health reform survive the Supreme Court?

    Merrill Goozner
  • a desk with keyboard and ipad with the kevinmd logo

    A look behind the growing cost of cancer drugs

    Merrill Goozner

More in Conditions

  • What Elon Musk and Diddy reveal about the price of power

    Osmund Agbo, MD
  • Understanding depression beyond biology: the power of therapy and meaning

    Maire Daugharty, MD
  • Why medicine must stop worshipping burnout and start valuing humanity

    Sarah White, APRN
  • Why perinatal mental health is the top cause of maternal death in the U.S.

    Sheila Noon
  • A world without vaccines: What history teaches us about public health

    Drew Remignanti, MD, MPH
  • Unraveling the mystery behind one of the most dangerous pregnancy complications: preeclampsia

    Thomas McElrath, MD, PhD and Kara Rood, MD
  • Most Popular

  • Past Week

    • Why are medical students turning away from primary care? [PODCAST]

      The Podcast by KevinMD | Podcast
    • Why “do no harm” might be harming modern medicine

      Sabooh S. Mubbashar, MD | Physician
    • How New Mexico became a malpractice lawsuit hotspot

      Patrick Hudson, MD | Physician
    • Why doctors are reclaiming control from burnout culture

      Maureen Gibbons, MD | Physician
    • Why health care leaders fail at execution—and how to fix it

      Dave Cummings, RN | Policy
    • 5 blind spots that stall physician wealth

      Johnny Medina, MSc | Finance
  • Past 6 Months

    • Why tracking cognitive load could save doctors and patients

      Hiba Fatima Hamid | Education
    • Why are medical students turning away from primary care? [PODCAST]

      The Podcast by KevinMD | Podcast
    • What the world must learn from the life and death of Hind Rajab

      Saba Qaiser, RN | Conditions
    • Why “do no harm” might be harming modern medicine

      Sabooh S. Mubbashar, MD | Physician
    • Here’s what providers really need in a modern EHR

      Laura Kohlhagen, MD, MBA | Tech
    • Why flashy AI tools won’t fix health care without real infrastructure

      David Carmouche, MD | Tech
  • Recent Posts

    • Why judgment is hurting doctors—and how mindfulness can heal

      Jessie Mahoney, MD | Physician
    • Why medical schools must ditch lectures and embrace active learning

      Arlen Meyers, MD, MBA | Education
    • Why helping people means more than getting an MD

      Vaishali Jha | Education
    • How digital tools are reshaping the doctor-patient relationship

      Vineet Vishwanath | Tech
    • Why evidence-based management may be an effective strategy for stronger health care leadership and equity

      Olumuyiwa Bamgbade, MD | Physician
    • Why health care leaders fail at execution—and how to fix it

      Dave Cummings, RN | Policy

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 1 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

  • Most Popular

  • Past Week

    • Why are medical students turning away from primary care? [PODCAST]

      The Podcast by KevinMD | Podcast
    • Why “do no harm” might be harming modern medicine

      Sabooh S. Mubbashar, MD | Physician
    • How New Mexico became a malpractice lawsuit hotspot

      Patrick Hudson, MD | Physician
    • Why doctors are reclaiming control from burnout culture

      Maureen Gibbons, MD | Physician
    • Why health care leaders fail at execution—and how to fix it

      Dave Cummings, RN | Policy
    • 5 blind spots that stall physician wealth

      Johnny Medina, MSc | Finance
  • Past 6 Months

    • Why tracking cognitive load could save doctors and patients

      Hiba Fatima Hamid | Education
    • Why are medical students turning away from primary care? [PODCAST]

      The Podcast by KevinMD | Podcast
    • What the world must learn from the life and death of Hind Rajab

      Saba Qaiser, RN | Conditions
    • Why “do no harm” might be harming modern medicine

      Sabooh S. Mubbashar, MD | Physician
    • Here’s what providers really need in a modern EHR

      Laura Kohlhagen, MD, MBA | Tech
    • Why flashy AI tools won’t fix health care without real infrastructure

      David Carmouche, MD | Tech
  • Recent Posts

    • Why judgment is hurting doctors—and how mindfulness can heal

      Jessie Mahoney, MD | Physician
    • Why medical schools must ditch lectures and embrace active learning

      Arlen Meyers, MD, MBA | Education
    • Why helping people means more than getting an MD

      Vaishali Jha | Education
    • How digital tools are reshaping the doctor-patient relationship

      Vineet Vishwanath | Tech
    • Why evidence-based management may be an effective strategy for stronger health care leadership and equity

      Olumuyiwa Bamgbade, MD | Physician
    • Why health care leaders fail at execution—and how to fix it

      Dave Cummings, RN | Policy

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Medicare’s high cost end stage renal disease patients
1 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...